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Hoeks, Joris, Marleen A. van Baak, Matthijs K. C.
Hesselink, Gabby B. Hul, Hubert Vidal, Wim H. M.
Saris, and Patrick Schrauwen. Effect of 1- and 2-adren-
ergic stimulation on energy expenditure, substrate oxidation,
and UCP3 expression in humans. Am J Physiol Endocrinol
Metab 285: E775–E782, 2003. First published June 24, 2003;
10.1152/ajpendo.00175.2003.—In humans, -adrenergic
stimulation increases energy and fat metabolism. In the case
of 1-adrenergic stimulation, it is fueled by an increased
lipolysis. We examined the effect of 2-adrenergic stimula-
tion, with and without a blocker of lipolysis, on thermogen-
esis and substrate oxidation. Furthermore, the effect of 1-
and 2-adrenergic stimulation on uncoupling protein 3
(UCP3) mRNA expression was studied. Nine lean males
received a 3-h infusion of dobutamine (DOB, 1) or salbuta-
mol (SAL, 2). Also, we combined SAL with acipimox to block
lipolysis (SALACI). Energy and substrate metabolism were
measured continuously, blood was sampled every 30 min,
and muscle biopsies were taken before and after infusion.
Energy expenditure significantly increased 13% in all con-
ditions. Fat oxidation increased 47  7% in the DOB group
and 19  7% in the SAL group but remained unchanged in
the SALACI condition. Glucose oxidation decreased 40 
9% upon DOB, remained unchanged during SAL, and in-
creased 27  11% upon SALACI. Plasma free fatty acid
(FFA) levels were increased by SAL (57  11%) and DOB
(47  16%), whereas SALACI caused about fourfold lower
FFA levels compared with basal levels. No change in UCP3
was found after DOB or SAL, whereas SALACI downregu-
lated skeletal muscle UCP3 mRNA levels 38  13%. In
conclusion, 2-adrenergic stimulation directly increased en-
ergy expenditure independently of plasma FFA levels. Fur-
thermore, this is the first study to demonstrate a downregu-
lation of skeletal muscle UCP3 mRNA expression after the
lowering of plasma FFA concentrations in humans, despite
an increase in energy expenditure upon 2-adrenergic stim-
ulation.
uncoupling protein 3; thermogenesis; adrenergic receptors;
sympathetic nervous system
IN RODENTS, THE MAJOR SITE of thermogenesis is the
brown adipose tissue (BAT), and a key molecule in BAT
thermogenesis is uncoupling protein 1 (UCP1). This
protein dissipates the mitochondrial proton gradient
by catalyzing the backflow of protons into the mito-
chondrial matrix, thereby generating heat (8). Sympa-
thetic stimulation increases energy expenditure in ro-
dents by several methods, one of which is by stimulat-
ing BAT thermogenesis (9). BAT contains all three
-adrenergic receptor subtypes, each of which is cou-
pled to a G protein to stimulate adenylate cyclase and,
thereby, the cAMP/PKA pathway (2).
In humans, both 1-adrenergic stimulation and 2-
adrenergic stimulation also increase energy expendi-
ture (19, 20). However, in contrast to rodents, -adren-
ergic-stimulated thermogenesis in humans is mainly
located in skeletal muscle (25, 26), and the mechanism
is still unknown. Besides increasing energy expendi-
ture, both 1- and 2-adrenergic stimulations also in-
crease adipose tissue lipolysis (19, 20), and it has been
shown that the increased lipolysis is responsible for a
great part of the increase in energy expenditure after
1-adrenergic stimulation (18). However, since 2-ad-
renergic receptors are mainly localized in skeletal mus-
cle and not in adipocytes, it can be hypothesized that
2-adrenergic stimulation may exert a direct effect on
energy expenditure. Therefore, the first aim of the
present study was to examine the effect of 2-adrener-
gic stimulation, with and without a blocker of lipolysis,
on energy and substrate metabolism.
As mentioned above, the mechanism through which
sympathetic stimulation might increase energy expen-
diture in skeletal muscle is still unknown. UCP3,
which shows 55% amino acid homology with UCP1
and is predominantly expressed in skeletal muscle (1,
28), has been reported to have uncoupling activity (5,
7). With respect to the possible role of UCP3 in human
thermogenesis, we reported that UCP3 mRNA expres-
sion was positively correlated with sleeping metabolic
rate in Pima Indians, suggesting that skeletal muscle
UCP3 is a mediator in the regulation of energy metab-
olism (24). More recently, however, we reported that
human UCP3 probably plays a role in fatty acid me-
tabolism, with uncoupling as a possible secondary ef-
fect (22, 23). Therefore, UCP3 could either directly or
indirectly be involved in -adrenergic receptor-stimu-
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lated thermogenesis. In this respect, animal and cell
culture studies have revealed controversial data re-
garding the effect of -adrenergic stimulation on UCP3
expression. Nakamura et al. (14) reported that skeletal
muscle UCP3 in mice was upregulated after treatment
with a 3-adrenergic agonist. However, free fatty acid
levels were also increased after 3-adrenergic stimula-
tion, which could have caused the observed effect on
UCP3 expression (29). In addition, Gomez-Abrosi et al.
(6) were unable to detect any changes in skeletal mus-
cle UCP3 expression upon short-term 3-adrenergic
stimulation in male Wistar rats. However, Nagase et
al. (13) showed that stimulation of L6 myotubes with
epinephrine increased UCP3 mRNA levels and that
the regulatory effects of catecholamines were mediated
through the 2-adrenergic receptor pathway. Regard-
less of the controversial data in animal studies and cell
culture systems, no data are currently available on the
effect of -adrenergic activity on UCP3 mRNA expres-
sion in human skeletal muscle.
Therefore, the second aim of the present study was to
examine the effect of -adrenergic stimulation (1 or
2) in healthy lean human subjects on the expression of
skeletal muscle UCP3 mRNA. Because high fatty acid
levels are known to upregulate UCP3 (11, 17, 29), we
examined the effect of 2-adrenergic stimulation on
UCP3 mRNA expression independent of the effect of
increased lipolysis.
MATERIALS AND METHODS
Subjects. Nine healthy lean male volunteers participated
in this study. Subject characteristics are displayed in Table 1.
All subjects were in good health as assessed by medical
history and physical examination. All subjects engaged in
sports activities 2 h/wk, and none had physically demand-
ing jobs.
The study protocol was reviewed and approved by the
Medical Ethics Committee of Maastricht University, and all
subjects gave written informed consent before participating
in the study.
Experimental design. Subjects arrived at the laboratory at
8:00 AM after an overnight fast. Subjects were asked to avoid
physical activity before the test. All subjects performed tests
under three different conditions in a randomized crossover
design. Between conditions, a washout period of 1 wk was
maintained.
On the subject’s arrival at the laboratory, a percutaneous
muscle biopsy was taken from the vastus lateralis muscle.
After local anesthesia (0.2% xylocaine without epinephrine),
a 5-mm-diameter side-cutting needle was passed through a
7-mm skin incision. The muscle biopsy was frozen immedi-
ately in liquid nitrogen and stored at 80°C until assayed.
Subsequently, two Teflon cannulas were inserted into an
antecubital vein of each arm. One cannula was used for the
infusion of -adrenergic agonists and one cannula for sam-
pling of blood. After the muscle biopsy was taken and can-
nulas were placed, subjects rested on a bed for 2 h to avoid
induction of endogenous stress hormone levels. Next, oxygen
consumption and carbon dioxide production were measured
for 30 min by use of a custom-made ventilated hood system
(Omnical, Maastricht University, The Netherlands). After 30
min, a first blood sample was taken (time 0). After this, a
continuous infusion of either 4.6 g  kgFFM1  min1 dobut-
amine (DOB, a selective 1-adrenergic receptor agonist;
Dobax, Zwanenburg, The Netherlands) or 77 ng  kgFFM1 
min1 salbutamol (SAL, a selective 2-adrenergic receptor
agonist; Ventolin, GlaxoSmithKline, Zeist, The Netherlands)
was started and maintained for 3 h. The third condition
(SALACI) consisted of salbutamol infusion combined with
simultaneous blocking of lipolysis by acipimox. To that pur-
pose, two doses of 250-mg acipimox were given orally at120
min and time 0. Blood samples were taken every 30 min, and
ventilated hood measurements were continued throughout
the experiment. After the 3 h of infusion, a second muscle
biopsy was taken.
Body composition. One week before the first test, body
density was determined by hydrostatic weighing in the morn-
ing in the fasted state. Body weight was measured with a
digital balance with an accuracy of 0.01 kg (Sauter, type
E1200). Lung volume was measured simultaneously with the
helium dilution technique by a spirometer (Volugraph 2000,
Mijnhardt). Body composition was calculated according to
the equation of Siri (27). Fat-free mass was calculated by
subtracting fat mass from total body weight.
Indirect calorimetry. Whole body energy expenditure and
substrate oxidation were measured by indirect calorimetry
by use of a custom-made ventilated hood system (Omnical,
Maastricht University, The Netherlands). The volume of air
drawn through the hood was measured by a dry gas meter
(Schlumberger, Dordrecht, The Netherlands), and the com-
position of the in- and outflowing air was analyzed by a
paramagnetic O2 analyzer (Servomex, Crowborough, UK)
and an infrared CO2 analyzer (Hartmann en Braun, Frank-
furt, Germany). The airflow rate and the O2 and CO2 concen-
trations were used to compute O2 consumption and CO2
production on-line through an automatic acquisition system
connected to a personal computer. O2 consumption and CO2
production were averaged over the last 15 min of each 30-min
time interval. Energy expenditure was calculated according
to the Weir formula (30). Total carbohydrate and fat oxida-
tion values were calculated using stoichiometric equations
(16).
Blood analysis. Blood for determination of plasma free
fatty acids (FFA) was collected in tubes containing 30 l of
0.2 M EDTA. Blood was immediately centrifuged at high
speed, and plasma was transferred to Eppendorf tubes.
Plasma was rapidly frozen in liquid nitrogen and stored at
20°C until further analysis. Plasma FFA concentrations
were measured using the Wako NEFA C kit (Wako Chemi-
cals, Neuss, Germany).
Quantitation of UCP3 mRNA. Total RNA was extracted
from skeletal muscle biopsies using TRIzol reagent (Invitro-
gen, Breda, The Netherlands). First-strand cDNAs were first
synthesized from 1 g of total RNA in the presence of 100
units of Superscript II (Invitrogen, Eragny, France) with use
of both random hexamers and oligo(dT) primers (Promega,
Charbonnie`res, France). Real-time PCR was performed using
a LightCycler (Roche Diagnostics, Meylan, France) in a final
volume of 20 l containing 5 l of a 100-fold dilution of the
Table 1. Subject characteristics
Means  SE
Body weight, kg 71.53.2
Fat-free mass, kg 58.02.7
Height, m 1.790.03
Body mass index, kg/m2 22.20.8
Age, yr 24.41.3
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reverse transcription reaction and 15 l of reaction buffer
from the FastStart DNA Master SYBR Green kit (Roche
Diagnostics) with 3 mM of MgCl2 and the specific forward
(5-ATGGACGCCTACAGAACCAT-3) and reverse (5-CTG-
GGCCACCATCTTTATCA-3) UCP3 primers (Sigma-Geno-
sys, Cambridgeshire, UK). After amplification, a melting
curve analysis was performed to verify the specificity of the
reaction. For quantification, a standard curve was systemat-
ically generated with six different amounts (150 to 30,000
molecules/tube) of human UCP3 cDNA cloned in the pGEM
plasmid (Promega). To correct for possible variations in the
efficiency of the reverse transcription, a reference gene (cy-
clophilin) was simultaneously measured using the specific
forward (5-GCCATGGAGCGCTTTGG-3) and reverse (5-
CCACAGTCACGAATGGTGATC-3) cyclophilin primers.
The levels of UCP3 mRNA were normalized to cyclophilin
mRNA expression and used as a housekeeping marker, and
values were expressed as the ratio of UCP3 and cyclophilin.
The analysis was performed using the LightCycler software
(Roche Diagnostics).
Statistical analysis. All values are expressed as means 
SE. Changes in energy expenditure, plasma FFAs, fat oxida-
tion, and glucose oxidation were calculated as total area
under the curve (AUC) minus baseline values. Differences
between conditions were evaluated by analysis of variance
(one-way ANOVA). When significant differences were found,
a Bonferroni adjusted post hoc test was used to determine the
exact location of the difference. Pre- and postexperimental
differences within groups were analyzed pairwise by Stu-
dent’s t-tests. Outcomes were regarded as statistically signif-
icant if P  0.05.
RESULTS
Energy expenditure and substrate oxidation. Base-
line energy expenditure was similar in all three condi-
tions [5.51  0.30, 5.24  0.35, and 4.97  0.28 kJ/min
in DOB, SAL, and SALACI, respectively, not signifi-
cant (NS)]. Upon -adrenergic stimulation, energy ex-
penditure increased and remained stable during the
entire 3-h infusion period (Fig. 1). Dobutamine (DOB)
infusion resulted in a 0.58  0.20 kJ/min (P  0.05)
increase in energy expenditure, whereas the SAL and
SALACI conditions showed a 0.72  0.12 (P  0.001)
and 0.62  0.12 (P  0.001) kJ/min increase, respec-
tively. No significant difference existed among condi-
tions regarding the increase in energy expenditure
(Fig. 2).
Figure 3 displays the changes in respiratory ex-
change ratio (RER) during the -adrenergic stimula-
tion. From this ratio, fat and glucose oxidation were
calculated. At baseline, fat oxidation was similar be-
tween conditions (81.5  5.7, 75.5  10.8, and 63.7 
9.2 mg/min in DOB, SAL, and SALACI respectively,
NS). Administration of dobutamine or salbutamol sig-
nificantly increased the oxidation of fatty acids by
38.0  5.9 and 14.3  5.5 mg/min, respectively (P 
0.05). The increase in fat oxidation after salbutamol
administration was completely absent when acipimox
was coadministered (1.0  6.8 mg/min; NS). The
increase in fat oxidation (Fig. 4A) was significantly
higher in the DOB condition than in either SAL or
SALACI condition (P  0.005).
Glucose oxidation did not show statistically signifi-
cant differences between conditions at baseline
(147.9  12.7, 146.2  23.7, and 158.5  13.9 mg/min
in DOB, SAL, and SALACI, respectively, NS). Glu-
cose oxidation (Fig. 4B) significantly decreased by
58.5  13.4 mg/min (P  0.005) upon dobutamine
administration, whereas no change was detected dur-
ing salbutamol infusion (10.3  11.8 mg/min, NS).
However, addition of acipimox to salbutamol signifi-
Fig. 1. Energy expenditure during
-adrenergic stimulation. Values are
means  SE. F, dobutamine (DOB); E,
salbutamol (SAL); , SALacipimox
(ACI).
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cantly increased glucose oxidation by 42.5  17.5 mg/
min (P  0.05).
Blood and muscle substrates. Baseline plasma FFA
concentrations were significantly lower after adminis-
tration of acipimox than after either the DOB or SAL
condition (67.0  13.3 vs. 443.7  72.2 and 341.3 
68.1 mol/l in SALACI vs. DOB and SAL, respec-
tively, P 0.001). Upon -adrenergic stimulation, FFA
levels significantly rose in all conditions (209  72,
196  37, and 57  19 mol/l in DOB, SAL, and
SALACI, respectively, P  0.05), although the in-
crease in plasma FFA in the SALACI condition was
approximately fourfold lower than during either dobut-
amine or salbutamol infusion (Fig. 5).
Basal UCP3 mRNA levels were not significantly dif-
ferent among the three conditions (DOB: 43 12; SAL:
52  14; SALACI: 79  12 arbitrary units, NS).
Simultaneous administration of salbutamol and acipi-
mox significantly lowered UCP3 mRNA levels 38 
13% (P  0.05). However, neither dobutamine nor
salbutamol administration alone altered UCP3 expres-
sion significantly (Fig. 6).
DISCUSSION
In rodents, UCP1, located in the inner mitochondrial
membranes of BAT, plays an important role in sympa-
thetic stimulation-induced adaptive thermogenesis
(10). In contrast, in humans, skeletal muscle is respon-
sible for a major part of -adrenergic-induced thermo-
genesis (25, 26). UCP3, primarily localized in skeletal
muscle (1, 28), is a candidate for explaining sympa-
thetic stimulation-induced adaptive thermogenesis,
but possible regulation of UCP3 expression by the
sympathetic nervous system has not yet been studied
in humans. Here, we show that 1- or 2-adrenergic
receptor stimulation is not involved in the regulation of
UCP3 mRNA expression.
In the present study, energy expenditure signifi-
cantly increased upon both 1- (dobutamine) and 2-
adrenergic stimulation (salbutamol). It was previously
shown that the increase in energy expenditure upon
1-adrenergic stimulation was an indirect effect, fueled
by plasma FFAs released from adipose tissue (18).
However, in contrast to 1-adrenergic receptors, 2-
adrenergic receptors are primarily located in skeletal
muscle; therefore, we hypothesized that the 2-adren-
ergic-induced increase in energy expenditure would be
Fig. 2. Changes in energy expenditure upon -adrenergic stimula-
tion. Values (means SE) are areas under the curve (AUC) of energy
expenditure vs. time minus baseline (kJ/min). Solid bar, DOB; gray
bar, SAL; hatched bar, SALACI. *P  0.05 vs. baseline.
Fig. 3. Respiratory exchange ratio during -adren-
ergic stimulation. Values are means  SE. F, DOB;
E, SAL; , SALACI.
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directly fueled by skeletal muscle. To this purpose, we
examined the effect of 2-adrenergic stimulation on
energy expenditure with and without acipimox to sup-
press lipolysis. Acipimox indeed effectively suppressed
lipolysis but did not affect the 2-adrenergic receptor-
mediated increase in energy expenditure. Thus the
2-adrenergic-induced increase in energy expenditure
is directly fueled by skeletal muscle energy sources and
is not mediated by increased plasma FFA levels.
The increase in energy expenditure upon 1-adren-
ergic receptor stimulation has been shown to be cov-
ered by an increased fat oxidation, and, again, this
increase was reduced when lipolysis was inhibited dur-
ing 1-adrenergic stimulation with dobutamine (18).
Also in the present study, dobutamine (1) as well as
salbutamol (2) administration significantly increased
fat oxidation compared with basal levels. However, the
increase in fat oxidation was 2.6-fold higher upon
1-adrenergic stimulation by dobutamine than upon
2-adrenergic stimulation by salbutamol, whereas the
rise in energy expenditure and plasma FFAs was com-
parable between the two conditions, indicating that
part of the increase in energy expenditure upon 2-
adrenergic stimulation was due to increased glucose
oxidation. Schiffelers et al. (19) also studied the in-
crease in fat oxidation after selective stimulation of the
1-adrenergic receptor by dobutamine as well as after
selective 2-adrenergic receptor stimulation by salbu-
tamol. In contradiction to our results, this study re-
vealed that when energy expenditure was equally in-
creased with certain concentrations of dobutamine and
salbutamol, the relative contribution of fat oxidation to
total energy expenditure was not different between 1-
and 2-adrenergic stimulation (19). However, in this
study by Schiffelers et al., subjects received consecu-
tive infusions of increasing concentrations of dobut-
amine and salbutamol, each dose for 30 min, whereas
in the present study, a fixed concentration was admin-
istered continuously for 3 h. In the present study,
administration of acipimox, to block lipolysis, completely
abolished the 2-induced increase in fat oxidation with-
out affecting energy expenditure, again indicating that
2-adrenergic stimulation directly influences glucose ox-
idation. This suggestion is underscored by the observa-
tion that the increase in fat oxidation was less pro-
nounced during 2-adrenergic stimulation than during
1-adrenergic stimulation despite a similar increase in
plasma FFAs and thermogenesis. Moreover, when
plasma FFAs were reduced by inhibiting lipolysis with
acipimox during 2-adrenergic stimulation, glucose oxi-
dation significantly increased by 27%, completely cov-
ering the increase in energy expenditure. Taken together,
these data indicate that, next to a small increase in fat
oxidation driven by increased lipolysis, 2-adrenergic
stimulation also directly increases glucose oxidation. Pre-
vious studies have shown that nonselective blockade of
all -adrenergic receptors impeded enhancement of exer-
cise-induced glycogenolysis in human skeletal muscle (4,
15). Chruscinski et al. (3) selectively disrupted the 2-
adrenergic receptor gene in mice and observed a lower
RER during exercise in the knockout mice, suggesting
that these mice may use a greater ratio of fat to carbo-
hydrate than wild-type mice. Because during exercise
glycogen provides a major part of the energy required,
this observation is consistent with a role for the 2-
adrenergic receptor in the mobilization of glycogen (3).
Specific 1-adrenergic effects on glycogenolysis in skele-
tal muscle are unknown but seem unlikely, since skeletal
muscle lacks 1-adrenergic receptors (12).
Fig. 4. Changes in fat and glucose oxidation upon -adrenergic
stimulation. Values (means  SE) are areas under the curve of fat
(A) or glucose oxidation (B) vs. time minus baseline (mg/min). Solid
bar, DOB; gray bar, SAL; hatched bar, SALACI. *P  0.05 vs.
baseline; #P  0.05 vs. SAL and SALACI.
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Independent of the substrate being oxidized, the
mechanism for the increased thermogenesis in skeletal
muscle upon -adrenergic stimulation is unknown. Be-
cause UCP3 is capable of uncoupling (5, 7) and is
primarily localized in skeletal muscle (1, 28), this pro-
tein is a potential mediator in this process. In the
present study, we examined whether UCP3 mRNA
expression is under regulation of the sympathetic ner-
vous system. We found that administration of dobut-
amine or salbutamol did not upregulate UCP3 mRNA
expression. Therefore, a stimulatory effect of 1- or
2-adrenergic activity on skeletal muscle UCP3 mRNA
expression cannot be concluded from the present study.
Even more, UCP3 mRNA levels were significantly de-
creased when acipimox was coadministered with sal-
butamol, further indicating that -adrenergic stimula-
tion in humans does not upregulate UCP3 expression.
However, low FFA levels seem to be responsible for the
observed downregulation of UCP3 mRNA upon simul-
taneous administration of salbutamol and acipimox,
further providing evidence for an important role of
FFA in the regulation of UCP3. It has already been
shown that high levels of plasma FFAs are able to
upregulate skeletal muscle UCP3 (11, 17, 29). Khalfal-
lah et al. (11) increased plasma FFA concentrations in
humans up to a final concentration of 989 mol/l dur-
ing triglyceride infusion and found a significant in-
crease in UCP3 mRNA. Furthermore, we showed that
acute exercise, a condition of increased energy expen-
diture, fat oxidation, and plasma FFA levels, upregu-
lated skeletal muscle UCP3 mRNA (21). In addition,
glucose ingestion, during and after exercise, abolished
the commonly observed increase in plasma FFA levels
and/or fatty acid oxidation and prevented the upregu-
lation of UCP3 after acute exercise, indicating that the
observed increase in UCP3 mRNA levels appeared to
be an effect of elevated plasma FFA levels and/or
increased fatty acid oxidation rather than an effect of
increased energy expenditure (21). The lack of increase
Fig. 5. Plasma free fatty acids (FFA)
during -adrenergic stimulation. Val-
ues are means  SE.
Fig. 6. Changes in uncoupling protein 3 (UCP3) mRNA levels after
-adrenergic stimulation. Values (means  SE) are postexperimen-
tal UCP3 mRNA levels minus preexperimental levels (arbitrary
units). *P  0.05 vs. baseline.
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in UCP3 mRNA levels upon 1- and 2-adrenergic
stimulation in the current study, despite increased
levels of plasma FFAs, might be explained by the fact
that plasma FFA levels reached 50% of the values
obtained by Khalfallah et al. (11) and our own labora-
tory (21). The present study is the first to show a
significant downregulation of skeletal muscle UCP3
mRNA levels upon low plasma FFA concentrations in
humans despite an increase in energy expenditure.
This finding further favors a role for fatty acids in the
regulation of UCP3 mRNA expression and suggests
that the physiological function of UCP3 is more likely
related to fatty acid metabolism than to the regulation
of energy expenditure. From the present study, how-
ever, we cannot exclude the possibility that UCP3
protein content or UCP3 activity is altered upon -ad-
renergic stimulation.
We recently suggested that UCP3 might act as a
mitochondrial fatty acid anion exporter to prevent ac-
cumulation of nonmetabolizable and potentially toxic
fatty acid anions inside the mitochondrial matrix (23),
and the acipimox-induced downregulation of UCP3 is
compatible with this hypothesis.
In conclusion, 3 h of infusion of both dobutamine (1)
and salbutamol (2) increased energy expenditure, fat
oxidation, and plasma FFA levels. In contrast to 1-
adrenergic stimulation, 2-adrenergic stimulation in-
creased energy expenditure independently of plasma
FFA levels. Furthermore, 2-adrenergic activity stim-
ulated glucose oxidation, most likely due to increased
glycogenolysis.
No evidence was found for a regulatory role for 1- or
2-adrenergic activity on skeletal muscle UCP3 expres-
sion in this study, since neither salbutamol nor dobut-
amine affected UCP3 expression. However, significant
downregulation of skeletal muscle UCP3 mRNA levels
was observed upon low plasma FFA concentrations in
humans, despite an increase in energy expenditure.
Therefore, changes in UCP3 mRNA expression seem to
be related to fatty acid metabolism rather than to
energy metabolism. However, future studies are
needed to reveal whether mitochondrial uncoupling,
for example by increasing UCP3 activity, is involved in
-adrenergic-induced adaptive thermogenesis.
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